Targeted therapies approved by the US Food and Drug Administration in R/R DLBCL, pivotal trials
| Characteristic . | Tafasitamab + lenalidomide . | Loncastuximab tesirine . | Rituximab-bendamustine-polatuzumab vedotin . | Selinexor . |
|---|---|---|---|---|
| Trial name | L-MIND13 | LOTIS-216 | R-Benda-Pola17 | SADAL19 |
| Sample size | 80 | 145 | 80 | 267 |
| ORR, % | 60 | 48 | 63 | 28 |
| Follow-up, mo | 17.3 | 7.3 | 27 | 14.7 |
| PFS, mo | 12.1 | 4.9 | 9.2 | 2.6 |
| OS, mo | Not reached | 9.9 | 12.4 | 9.1 |
| DOR, mo | 21.7 | 10.3 | 10.9 | 9.3 |
| ORR post-CART, % | 36 (n = 42)15 | 46 (n = 13)28 | 44 (n = 57)29 | — |
| PFS after CAR T-cell, mo | 1.4 | 1.4 | 2.5 | — |
| Characteristic . | Tafasitamab + lenalidomide . | Loncastuximab tesirine . | Rituximab-bendamustine-polatuzumab vedotin . | Selinexor . |
|---|---|---|---|---|
| Trial name | L-MIND13 | LOTIS-216 | R-Benda-Pola17 | SADAL19 |
| Sample size | 80 | 145 | 80 | 267 |
| ORR, % | 60 | 48 | 63 | 28 |
| Follow-up, mo | 17.3 | 7.3 | 27 | 14.7 |
| PFS, mo | 12.1 | 4.9 | 9.2 | 2.6 |
| OS, mo | Not reached | 9.9 | 12.4 | 9.1 |
| DOR, mo | 21.7 | 10.3 | 10.9 | 9.3 |
| ORR post-CART, % | 36 (n = 42)15 | 46 (n = 13)28 | 44 (n = 57)29 | — |
| PFS after CAR T-cell, mo | 1.4 | 1.4 | 2.5 | — |
Benda, bendamustine; DOR, duration of response; Pola, polatuzumab vedotin; R/R, relapsed/refractory.